The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
N-(2,3-dihydrobenzofuran-4-ylmethyl)-8-(3-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine ID: ALA5205327
PubChem CID: 121432827
Max Phase: Preclinical
Molecular Formula: C19H16N6O
Molecular Weight: 344.38
Associated Items:
Names and Identifiers Canonical SMILES: c1cncc(-c2cnc(NCc3cccc4c3CCO4)n3cnnc23)c1
Standard InChI: InChI=1S/C19H16N6O/c1-3-14(15-6-8-26-17(15)5-1)10-21-19-22-11-16(13-4-2-7-20-9-13)18-24-23-12-25(18)19/h1-5,7,9,11-12H,6,8,10H2,(H,21,22)
Standard InChI Key: VFLXVDWCZHLLLM-UHFFFAOYSA-N
Molfile:
RDKit 2D
26 30 0 0 0 0 0 0 0 0999 V2000
-1.0691 1.0310 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.3547 1.4435 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.3598 1.0310 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.3598 0.2060 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-0.3547 -0.2064 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.0691 0.2060 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-1.8537 1.2860 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-1.8537 -0.0488 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.3386 0.6186 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-0.3547 2.2683 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.0688 2.6809 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.0681 3.5032 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-0.3536 3.9157 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.3578 3.5067 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.3626 2.6824 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.3547 -1.0311 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
0.3595 -1.4435 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.3595 -2.2683 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.0737 -2.6809 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.0729 -3.5032 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.3585 -3.9157 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.3529 -3.5067 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.3577 -2.6824 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.8547 -3.7580 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
1.8559 -2.4275 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.3386 -3.0933 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1 2 1 0
3 2 2 0
4 3 1 0
5 4 2 0
1 6 1 0
6 5 1 0
1 7 2 0
6 8 1 0
8 9 2 0
9 7 1 0
10 2 1 0
11 10 2 0
12 11 1 0
13 12 2 0
14 13 1 0
10 15 1 0
15 14 2 0
5 16 1 0
16 17 1 0
17 18 1 0
19 18 2 0
20 19 1 0
21 20 2 0
22 21 1 0
23 22 2 0
18 23 1 0
20 24 1 0
19 25 1 0
25 26 1 0
26 24 1 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Topical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 344.38Molecular Weight (Monoisotopic): 344.1386AlogP: 2.73#Rotatable Bonds: 4Polar Surface Area: 77.23Molecular Species: NEUTRALHBA: 7HBD: 1#RO5 Violations: ┄HBA (Lipinski): 7HBD (Lipinski): 1#RO5 Violations (Lipinski): ┄CX Acidic pKa: ┄CX Basic pKa: 4.46CX LogP: 0.79CX LogD: 0.79Aromatic Rings: 4Heavy Atoms: 26QED Weighted: 0.61Np Likeness Score: -1.20
References 1. Huang Y, Sendzik M, Zhang J, Gao Z, Sun Y, Wang L, Gu J, Zhao K, Yu Z, Zhang L, Zhang Q, Blanz J, Chen Z, Dubost V, Fang D, Feng L, Fu X, Kiffe M, Li L, Luo F, Luo X, Mi Y, Mistry P, Pearson D, Piaia A, Scheufler C, Terranova R, Weiss A, Zeng J, Zhang H, Zhang J, Zhao M, Dillon MP, Jeay S, Qi W, Moggs J, Pissot-Soldermann C, Li E, Atadja P, Lingel A, Oyang C.. (2022) Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced Malignancies., 65 (7.0): [PMID:35352560 ] [10.1021/acs.jmedchem.1c02148 ]